"Adenine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A purine base and a fundamental unit of ADENINE NUCLEOTIDES.
| Descriptor ID |
D000225
|
| MeSH Number(s) |
D03.633.100.759.138
|
| Concept/Terms |
Adenine- Adenine
- Vitamin B 4
- 4, Vitamin B
- B 4, Vitamin
|
Below are MeSH descriptors whose meaning is more general than "Adenine".
Below are MeSH descriptors whose meaning is more specific than "Adenine".
This graph shows the total number of publications written about "Adenine" by people in this website by year, and whether "Adenine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 2 | 3 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 2 | 3 |
| 2015 | 0 | 4 | 4 |
| 2016 | 0 | 7 | 7 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 13 | 13 |
| 2019 | 0 | 7 | 7 |
| 2020 | 5 | 2 | 7 |
| 2021 | 6 | 3 | 9 |
| 2022 | 0 | 5 | 5 |
| 2023 | 2 | 3 | 5 |
| 2024 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adenine" by people in Profiles.
-
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood. 2024 Dec 26; 144(26):2706-2717.
-
Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD. Blood. 2024 Dec 19; 144(25):2678-2681.
-
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024 Dec; 21(12):867-887.
-
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv. 2024 09 10; 8(17):4487-4501.
-
Enterococcus faecalis-derived adenine enhances enterohaemorrhagic Escherichia coli Type 3 Secretion System-dependent virulence. Nat Microbiol. 2024 Sep; 9(9):2448-2461.
-
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. PLoS One. 2024; 19(4):e0289902.
-
VHL governs m6A modification and PIK3R3 mRNA stability in clear cell renal cell carcinomas. J Clin Invest. 2024 Apr 15; 134(8).
-
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr?m macroglobulinemia. Blood Adv. 2024 04 09; 8(7):1639-1650.
-
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Adv. 2024 02 27; 8(4):842-845.
-
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.